American Heart Association

SanBio’s stroke stem cell treatment receives innovation award from American Heart Association

Tuesday, February 28, 2017

SanBio, a provider of regenerative medicine for neurological disorders, announced that a recent publication of its novel stem cell treatment, SB623, for patients following a stroke, has received a prestigious award from the American Heart Association. The scientific article, “Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase I/IIa Study,” was the third prize winner of the 2016 Stroke Progress and Innovation Award.

[Read More]

AHA, Amazon launch cloud-based precision medicine data marketplace

Tuesday, November 15, 2016

The American Heart Association (AHA) announced a milestone in its strategic collaboration with Amazon Web Services (AWS)—the launch of a global, secure cloud-based data marketplace that will help revolutionize how researchers and clinicians come together as one community to access and analyze rich and diverse data to accelerate solutions for cardiovascular diseases—the No. 1 cause of death worldwide. 

[Read More]

AHA, Verily, AstraZeneca announce One Brave Idea Research Award Winner

Tuesday, October 11, 2016

The American Heart Association (AHA), Verily Life Sciences (formerly Google Life Sciences), an Alphabet company, and AstraZeneca, have announced that the One Brave Idea research award will be granted to Dr. Calum MacRae, chief of Cardiovascular Medicine at Boston’s Brigham and Women’s Hospital, to support his visionary approach to understanding and addressing coronary heart disease (CHD) and its devastating consequences.

[Read More]

Heart Association, Google collaborate on heart disease

Thursday, November 12, 2015

The American Heart Association (AHA) and Google Life Sciences (GLS) have announced a joint commitment to form a research collaboration that will bring new, unconventional thinking to one of the longstanding challenges of cardiovascular disease. Each organization will invest $25 million for a total of $50 million over roughly five years to support novel strategies to understand, prevent and reverse coronary heart disease and its consequences, such as heart failure and sudden cardiac death.

[Read More]

Boehringer Ingelheim planning two global trials of Pradaxa

Tuesday, November 26, 2013

Boehringer Ingelheim Pharmaceuticals plans to initiate two new global clinical trials of PRADAXA. One of the new trials, RE-DUAL PCI (Randomized Evaluation of Dual Therapy with Dabigatran v. Triple Therapy Strategy with Warfarin in Patients with NVAF that have undergone PCI with Stenting), is designed to evaluate the efficacy and safety of PRADAXA in patients with non-valvular atrial fibrillation (NVAF) who have undergone percutaneous coronary intervention (PCI), also known as angioplasty, with stent placement. The second of the new trials, RE-SPECT ESUS(TM) (Randomized Evaluation in Secondary stroke Prevention Comparing the Thrombin inhibitor dabigatran etexilate v. ASA in Embolic Stroke of Undetermined Source), is designed to evaluate the efficacy and safety of PRADAXA as a secondary stroke prevention therapy in patients who have suffered an embolic stroke of undetermined source (ESUS). Embolic strokes occur when a blood clot forms somewhere in the body and travels through the bloodstream to the brain.

[Read More]